- Active not recruitingPHASE3
Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)
This study looks at a new drug combination, acasunlimab and pembrolizumab, for a type of lung cancer that has spread or is advanced. It compares this combination to a standard chemotherapy, docetaxel, in people who have already had certain other treatments.
For: PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLCUnited States · Argentina · Australia - Active not recruitingPHASE2
Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer
This study is testing a new cancer medicine, acasunlimab, alone or with another drug, pembrolizumab, for a common type of lung cancer that has come back. It aims to see how safe and effective these treatments are.
For: Non Small Cell Lung Cancer MetastaticUnited States · France · Germany